Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sobetirome - NeuroVia

Next Previous
X
Search
Drug Profile

Sobetirome - NeuroVia

Alternative Names: GC-1; NV 1205; QRX-431

Latest Information Update: 17 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer NeuroVia; QuatRx Pharmaceuticals; University of California at San Francisco
  • Class Acetic acids; Antihyperlipidaemics; Benzhydryl compounds; Obesity therapies; Phenols; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Adrenoleucodystrophy
  • Discontinued Lipid metabolism disorders; Obesity

Most Recent Events

  • 13 May 2022 Pharmacodynamics data from a preclinical study in Idiopathic pulmonary fibrosis presented at the 118th International Conference of the American Thoracic Society(ATS-2022)
  • 06 Mar 2019 NeuroVia withdraws a phase I/II trial prior to enrolment due to no funding in Adrenoleucodystrophy (In children, In adolescents) in Australia, United Kingdom, Chile (PO) (NCT03196765)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Adrenoleucodystrophy in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top